{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:56:48Z","timestamp":1776401808244,"version":"3.51.2"},"reference-count":29,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Meningococcal disease is primarily caused by serogroups A, B, C, W, and Y. Current US vaccination recommendations include routine serogroup A\/C\/W\/Y (MenACWY) vaccination (ages 11\u201312 and 16 years) and a two-dose, 0-, 6-month MenB vaccination series (age 16\u201323 years) based on shared clinical decision-making. Administration of the first-in-class Pfizer pentavalent MenABCWY vaccine (PenbrayaTM), which received US licensure in 2023 as a two-dose, 0-, 6-month series, is endorsed when the MenACWY and MenB vaccines are recommended at the same visit. This study evaluated the immunogenicity and safety of two extended two-dose schedules of MenABCWY in healthy adolescents. Methods: In this observer-blinded, phase 2b study (ClinicalTrials.gov, NCT04440176; 19 June 2020), 309 healthy 11- to 14-year-olds were randomized 1:1 to receive a 0-, 36-month or 0-, 12-month Pfizer MenABCWY schedule, which more closely aligns with current US MenACWY vaccination recommendations. Endpoints included serum bactericidal assay using human complement seroprotection rates (titers \u2265 1:8 or \u22651:16, depending on strain), seroresponse rates (\u22654-fold increase from baseline titer), and geometric mean titers (GMTs). Safety was also assessed. Results: One month after the second Pfizer MenABCWY dose, serogroup A\/B\/C\/W\/Y seroprotection rates were 100% for the 0-, 36-month schedule and 96.6\u2013100% for the 0-, 12-month schedule; seroresponse rates were 100% and 92.9\u2013100%, respectively. GMTs generally trended higher with the 0-, 36-month schedule. Seroprotection rates through 24 months after the second dose of the 0-, 12-month schedule were 44.0\u201375.0% for serogroup B and 88.9\u2013100% for serogroup A\/C\/W\/Y). No safety issues were identified. Conclusions: These data support Pfizer MenABCWY dosing flexibility and utility within the current or possible future US meningococcal vaccination framework.<\/jats:p>","DOI":"10.3390\/vaccines14040352","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:02:33Z","timestamp":1776261753000},"page":"352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Jake C.","family":"Jones","sequence":"first","affiliation":[{"name":"Wasatch Pediatrics, Murray, UT 84107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-521X","authenticated-orcid":false,"given":"Mary D.","family":"Tipton","sequence":"additional","affiliation":[{"name":"CopperView Medical Center, South Jordan, UT 84095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lefteris","family":"Zolotas","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Marlow SL7 1YL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Belanger","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, NY 10965, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, NY 10965, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-1791","authenticated-orcid":false,"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Pfizer US Vaccines Medical Affairs, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[{"name":"Pfizer US Vaccines Medical Affairs, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Marlow SL7 1YL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref_1","unstructured":"US Centers for Disease Control and Prevention (2024, October 30). Manual for the Surveillance of Vaccine-Preventable Diseases: Chapter 8: Meningococcal Disease, Available online: https:\/\/www.cdc.gov\/surv-manual\/php\/table-of-contents\/chapter-8-meningococcal-disease.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11910-015-0524-6","article-title":"Invasive meningococcal disease in the 21st century\u2014An update for the clinician","volume":"15","author":"Dwilow","year":"2015","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shen, J., Begum, N., Ruiz-Garcia, Y., Martinon-Torres, F., Bekkat-Berkani, R., and Meszaros, K. (2022). Range of invasive meningococcal disease sequelae and health economic application\u2014A systematic and clinical review. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-13342-2"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mathur, G., Domachowske, J.B., Gra\u00f1a, M.G., Ladak, R., Langley, J.M., Olaiya, O., Pompeo, A., Taddei, L., and Villena, R. (2025). Need for invasive meningococcal disease prevention through vaccination for young children in the Americas. Vaccines, 13.","DOI":"10.3390\/vaccines13090974"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yezli, S., Bonanni, P., Dinleyici, E.C., Divyesh, T., Kumar, V., Leng, S., Coste, F., and Taha, M.K. (2026). Invasive meningococcal disease rebound in older adults post-COVID-19 pandemic: A targeted literature and surveillance review. Int. J. Infect. Dis., 108502.","DOI":"10.1016\/j.ijid.2026.108502"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","article-title":"The important lessons lurking in the history of meningococcal epidemiology","volume":"23","author":"Borrow","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_9","unstructured":"Pfizer Inc (2025, June 06). FDA Approves PENBRAYATM, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-penbrayatm-first-and-only-vaccine-prevention."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","article-title":"Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"73","author":"Collins","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_11","unstructured":"(2023). PenbrayaTM (meningococcal groups A, B, C, W, and Y vaccine). Full Prescribing Information, Pfizer Ireland Pharmaceuticals."},{"key":"ref_12","unstructured":"Centers for Disease Control and Prevention (2025, December 22). Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger: United States 2025, Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/downloads\/child\/0-18yrs-child-combined-schedule.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.15585\/mmwr.mm7333a1","article-title":"National vaccination coverage among adolescents aged 13-17 years\u2014National Immunization Survey-Teen, United States, 2023","volume":"73","author":"Pingali","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_14","unstructured":"Centers for Disease Control and Prevention (2025, December 22). ACIP Recommendations, August 2025, Available online: https:\/\/www.cdc.gov\/acip\/vaccine-recommendations\/index.html."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00431-019-03511-8","article-title":"Experts\u2019 opinion for improving global adolescent vaccination rates: A call to action","volume":"179","author":"Azzari","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_16","unstructured":"(2025, July 29). Trumenba\u00ae (Meningococcal Group B Vaccine). Available online: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=1796."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","article-title":"From research to licensure and beyond: Clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine","volume":"17","author":"Perez","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"126469","DOI":"10.1016\/j.vaccine.2024.126469","article-title":"Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose","volume":"43","author":"Peterson","year":"2025","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.vaccine.2021.11.053","article-title":"A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults","volume":"40","author":"Drazan","year":"2022","journal-title":"Vaccine"},{"key":"ref_21","unstructured":"Ostergaard, L., Czajka, H., Roque-Guerrero, L., Maguire, J., Pregaldien, J.-L., Zolotas, L., Moughan, B., Maansson, R., O\u2019Neill, R., and Balmer, P. (2023, January 8\u201312). Phase 3, Randomized, Active-Controlled Trial Demonstrates Noninferiority of Pentavalent Meningococcal MenABCWY Vaccine to MenB-fHbp + MenACWY-CRM, Providing a High Degree of Protective Immunity in Healthy 10- to 25-Year-Olds. Proceedings of the European Society for Paediatric Infectious Diseases (ESPID), Lisbon, Portugal."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jcpt.13083","article-title":"A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp","volume":"45","author":"Burman","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_23","unstructured":"Centers for Disease Control and Prevention (2025, June 06). Meningococcal Disease Surveillance and Trends, Available online: https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/index.html."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1080\/21645515.2021.1968214","article-title":"Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses\u2014Results from two phase 2b randomized trials in adolescents","volume":"17","author":"Vesikari","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15\u201325 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/CDLI.7.5.764-768.2000","article-title":"Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines","volume":"7","author":"Sikkema","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0154-0","article-title":"Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine","volume":"5","author":"Harris","year":"2020","journal-title":"npj Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:17:58Z","timestamp":1776399478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["vaccines14040352"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14040352","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}